---
title: "Why Is Bristol-Myers Squibb Stock Surging Monday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294697898.md"
description: "Bristol-Myers Squibb stock surged following reports of merger talks with AstraZeneca, potentially creating a $400 billion pharmaceutical giant. The deal would make AstraZeneca the world's fourth-largest drugmaker and expand its U.S. presence, though it faces potential antitrust scrutiny due to overlapping oncology divisions. While discussions have continued for months, the final structure remains undecided, and delays or collapse are possible."
datetime: "2026-08-03T12:42:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294697898.md)
  - [en](https://longbridge.com/en/news/294697898.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294697898.md)
generator: "portal-rs"
---

# Why Is Bristol-Myers Squibb Stock Surging Monday?

**Bristol-Myers Squibb Company** (NYSE:BMY) stock traded higher on Monday following reports that the company is in discussions to merge with **AstraZeneca Plc** (NASDAQ:AZN).

The potential combination could create a pharmaceutical giant valued at nearly $400 billion. AstraZeneca holds an estimated market capitalization of $263 billion, while Bristol-Myers Squibb has a valuation of approximately $133 billion.

A completed deal would position AstraZeneca as the world’s fourth-largest drugmaker by market value.

 **Read Also: Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger** 

## Ongoing Discussions And Deal Terms

Talks between the two firms have continued for several months and could soon yield an agreement. However, delays or a total collapse remain possible, according to a report published by the Financial Times on Sunday.

The report indicated that the final structure remains undecided but would likely involve a combination of cash and stock.

## Expanding U.S. Presence And Regulatory Scrutiny

The proposed transaction would expand AstraZeneca’s footprint in the U.S. market following the recent elevation of its New York listing.

Because both companies operate substantial cancer divisions, any transaction could face significant antitrust scrutiny. The combination would rank as AstraZeneca’s largest acquisition, surpassing its $39 billion purchase of Alexion in 2021.

AstraZeneca recently reported a 6% increase in revenue, driven primarily by its oncology portfolio.

Meanwhile, Bristol-Myers Squibb continues to enhance its drug discovery capabilities through artificial intelligence partnerships, including an ongoing collaboration with **Anthropic**.

**BMY Stock Price Activity:** Bristol-Myers Squibb shares were up 4.88% at $68.50 during premarket trading on Monday, according to Benzinga Pro data.

*Image via Shutterstock*

 **Read Also: American Bitcoin Q2 Earnings Loom—Eric Trump’s Bitcoin Accumulation Play Faces Investor Scrutiny**

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [ABTC.US](https://longbridge.com/en/quote/ABTC.US.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [Cramer's lightning round: 'I am not going to put my money on AstraZeneca'](https://longbridge.com/en/news/298373941.md)
- [Bristol-Myers Squibb (BMY) Following Camzyos Data And Zola Cel Pause Still Looks Fully Valued](https://longbridge.com/en/news/298117403.md)
- [Bristol Myers Swoons on Test Results](https://longbridge.com/en/news/298335284.md)
- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)
- [AZ goes full AI-animal in new Breztri ad](https://longbridge.com/en/news/298129046.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**